WE CLAIM:

1. An anti-C5 antibody, wherein the antibody binds to C5 and inhibits complement dependent hemolysis, but does not block C5a formation, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain

the light chain sequence comprising a CDR1 comprising SEQ ID NO: 43, a CDR2 comprising SEQ ID NO: 44; and a CDR3 comprising SEQ ID NO: 45;

and the heavy chain sequence comprising: (i) a CDR1 comprising SEQ ID NO: 46; (ii) a CDR2 comprising SEQ ID NO: 47; and (iii) a CDR3 comprising SEQ ID NO: 48.

2. The antibody of claim 1, wherein the antibody blocks C5 binding to human Complement Component 6 and/or 7; and/or wherein the antibody inhibits formation of membrane attack complex (MAC).

3. The antibody of any one of claims 1 or 2, wherein the light chain comprises an amino acid sequence identical to SEQ ID NO: 3; and the heavy chain comprises an amino acid sequence identical to SEQ ID NO: 10.

4. The antibody of any one or more of the preceding claims, wherein the antibody is a monoclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof, or wherein the antibody is an antibody fragment and the antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule, and/or wherein said antibody is of the lgG1-, lgG2-, lgG3- or lgG4-type, preferably an lgG1-type.

5. The antibody of any one or more of the preceding claims, wherein the antibody is coupled to a labelling group, preferably wherein the labelling group is selected from an optical label, radioisotope, radionuclide, an enzymatic group, and a biotinyl group.

6. A process for preparing an isolated antibody according to any one or more of the preceding claims, comprising preparing said antibody from a host cell that secretes said antibody.

7. A nucleic acid molecule encoding an isolated antibody according to any one or more of the preceding claims.

8. The nucleic acid molecule according to claim 7, wherein the nucleic acid molecule is operably linked to a control sequence.

9. A pharmaceutical composition comprising at least one antibody according to any one or more of the preceding claims 1-5, and pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9, further comprising an additional active agent.

11. Use of the antibody of any one or more of the preceding claims 1-5, or the pharmaceutical composition according to claim 9 or 10, in the manufacture of a medicament for treating an indication associated with complement activation in a patient in need of treatment, wherein the indication is an ocular condition.

~~13~~12. The use of claim 11, wherein the ocular condition is age-related macular degeneration.